Enhanced Liver Fibrosis (ELF) Score
- $858
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
ENHANCED LIVER FIBROSIS
The Enhanced Liver Fibrosis (ELF) Score test contains 1 test with 1 biomarker .
Clinical Significance
Enhanced Liver Fibrosis (ELF) Score - The Enhanced Liver Fibrosis (ELF) score predicts progression to cirrhosis and liver-related events in patients with advanced fibrosis due to NASH.
The ELF score is not for use in the diagnosis of NASH, the staging of fibrosis, the serial monitoring of disease progression, or the monitoring of effects of therapeutic products.
The ELF score is derived from an algorithm that combines measurements of PIIINP, TIMP-1, and HA. PIIINP is a marker of early fibrogenesis and inflammation, TIMP-1 is the circulating inhibitor of MMP enzymes that can enhance fibrogenesis, and HA is a glycosaminoglycan that is produced by hepatic stellate cells. Together, these assays measure qualitative and quantitative changes in the extracellular matrix (ECM). The ECM refers to a set of macromolecules that comprise the extracellular scaffolding of the liver. Some ECM markers reflect fibrogenesis and others reflect fibrosis regression, allowing for a dynamic evaluation of ECM activity.
ELF score ranges and associated risk of disease progression (development of cirrhosis or liver-related events):
|
<9.80 |
Lower |
|
≥9.80 - <11.30 |
Mid |
|
≥11.30 |
Higher |